Surrozen Stock Based Compensation Over Time
| SRZN Stock | USD 12.20 1.98 19.37% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Surrozen Performance and Surrozen Correlation. Surrozen |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Surrozen. If investors know Surrozen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Surrozen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (16.94) | Revenue Per Share 3.804 | Return On Assets (0.33) | Return On Equity (1.74) |
The market value of Surrozen is measured differently than its book value, which is the value of Surrozen that is recorded on the company's balance sheet. Investors also form their own opinion of Surrozen's value that differs from its market value or its book value, called intrinsic value, which is Surrozen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Surrozen's market value can be influenced by many factors that don't directly affect Surrozen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Surrozen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Surrozen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Surrozen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Stock Based Compensation Analysis
Compare Surrozen and related stocks such as Bolt Biotherapeutics, Larimar Therapeutics, and Keros Therapeutics Stock Based Compensation Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BOLT | 123 K | 123 K | 123 K | 123 K | 123 K | 123 K | 123 K | 123 K | 123 K | 508 K | 1.4 M | 8.5 M | 9.6 M | 9.2 M | 5.4 M |
| LRMR | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 8.6 M | 173 K | 173 K | 173 K | 129 K | 2.2 M | 5.5 M | 6.6 M | 7.6 M | 4.4 M |
| KROS | 81 K | 81 K | 81 K | 81 K | 81 K | 81 K | 81 K | 81 K | 81 K | 59 K | 4.1 M | 11.7 M | 18.7 M | 28.8 M | 30.2 M |
| KZR | 128 K | 128 K | 128 K | 128 K | 128 K | 128 K | 128 K | 203 K | 2 M | 4 M | 4.9 M | 7.6 M | 14 M | 18.1 M | 19 M |
| PCSA | 457 K | 457 K | 457 K | 216.1 K | 231.5 K | 96.9 K | 96.9 K | 6.7 K | 74.1 K | 510.5 K | 2.7 M | 3.4 M | 8.8 M | 1.1 M | 1.8 M |
| TPST | 1.4 M | 1.4 M | 1.4 M | 5.1 M | 12.4 M | 19.3 M | 9.2 M | 6.9 M | 1.4 M | 310 K | 453 K | 1.1 M | 1.6 M | 2.5 M | 4.1 M |
| REPL | 208 K | 208 K | 208 K | 208 K | 208 K | 208 K | 208 K | 812 K | 2.7 M | 7.7 M | 11.8 M | 24.3 M | 28.1 M | 34.1 M | 35.8 M |
| NVCT | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.7 M | 4.7 M | 3 M |
| LYRA | 406 K | 406 K | 406 K | 406 K | 406 K | 406 K | 406 K | 406 K | 406 K | 244 K | 1.8 M | 2.8 M | 5.4 M | 5.9 M | 3 M |
| KRON | 30 K | 30 K | 30 K | 30 K | 30 K | 30 K | 30 K | 30 K | 30 K | 113 K | 3.8 M | 26.2 M | 31.1 M | 25 M | 15.8 M |
| GOSS | 32 K | 32 K | 32 K | 32 K | 32 K | 32 K | 32 K | 32 K | 30.9 M | 20.8 M | 38.7 M | 32 M | 42.6 M | 28.5 M | 30.4 M |
| APM | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.5 M | 1.7 M | 1.6 M | 1.3 M | 1.2 M |
| UNCY | 24 K | 24 K | 24 K | 24 K | 24 K | 24 K | 24 K | 24 K | 24 K | 24 K | 232 K | 966 K | 1 M | 1.8 M | 887.9 K |
| ARMP | 80 K | 9 K | 9 K | 1.4 M | 1.9 M | 483 K | 2 M | 700 K | 478 K | 4.3 M | 3.5 M | 2.9 M | 3.1 M | 938 K | 1.7 M |
| CTMX | 343 K | 343 K | 343 K | 343 K | 553 K | 4 M | 10.1 M | 11.3 M | 16.9 M | 19.1 M | 14.8 M | 13.2 M | 13.1 M | 8.6 M | 11.2 M |
| TIL | 293 K | 293 K | 293 K | 293 K | 293 K | 293 K | 293 K | 293 K | 293 K | 293 K | 1.7 M | 26.2 M | 30.4 M | 18.2 M | 16.9 M |
| SPRO | 21 K | 21 K | 21 K | 21 K | 21 K | 21 K | 180 K | 1.4 M | 2.7 M | 3.8 M | 4.9 M | 9.4 M | 9.1 M | 7.9 M | 4.8 M |
| ASMB | 460.8 K | 3 M | 3.2 M | 1.7 M | 11.3 M | 7.9 M | 5 M | 8.6 M | 28.5 M | 20.6 M | 21.9 M | 5.2 M | 6.6 M | 5.1 M | 9 M |
Surrozen and related stocks such as Bolt Biotherapeutics, Larimar Therapeutics, and Keros Therapeutics Stock Based Compensation description
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.My Equities
My Current Equities and Potential Positions
| Surrozen | SRZN |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 12.2
Check out Surrozen Performance and Surrozen Correlation. To learn how to invest in Surrozen Stock, please use our How to Invest in Surrozen guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Surrozen technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.